Johnson & Johnson (JNJ) Asset Utilization Ratio (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Asset Utilization Ratio came in at 0.48 in Q1 2026, up 0.77% year-on-year from 0.48 in Q1 2025, and little changed quarter-over-quarter from 0.48 in Q4 2025.
Johnson & Johnson (JNJ) Asset Utilization Ratio (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Asset Utilization Ratio across 18 years of filings, most recently posting 0.48 for Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.48, up 0.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.48 (up 0.77% YoY), and the FY2025 annual result was 0.5, down 2.8% from the prior year.
- Asset Utilization Ratio came in at 0.48 for Q1 2026 at Johnson & Johnson, roughly flat from 0.48 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.51 in Q4 2023 to a low of 0.42 in Q2 2023.
- The 5-year median for Asset Utilization Ratio is 0.48 (2025), against an average of 0.48.
- Across the five-year window, Asset Utilization Ratio decreased 14.21% in 2023 and gained 19.32% in 2024, its largest moves.
- Johnson & Johnson's Asset Utilization Ratio stood at 0.47 in 2022, then rose by 8.01% to 0.51 in 2023, then dropped by 2.91% to 0.5 in 2024, then fell by 3.05% to 0.48 in 2025, then grew by 0.24% to 0.48 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.48 (Q1 2026), 0.48 (Q4 2025), and 0.48 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 0.53 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.63 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.48 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.46 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.50 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.41 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.52 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.12 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 0.55 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 0.48 |
| Dec 28, 2025 | 0.48 |
| Sep 28, 2025 | 0.48 |
| Jun 29, 2025 | 0.47 |
| Mar 30, 2025 | 0.48 |
| Dec 29, 2024 | 0.50 |
| Sep 29, 2024 | 0.49 |
| Jun 30, 2024 | 0.49 |
| Mar 31, 2024 | 0.50 |
| Dec 31, 2023 | 0.51 |
| Oct 1, 2023 | 0.47 |
| Jul 2, 2023 | 0.42 |
| Apr 2, 2023 | 0.42 |
| Jan 1, 2023 | 0.44 |
| Oct 2, 2022 | 0.47 |
| Jul 3, 2022 | 0.49 |
| Apr 3, 2022 | 0.49 |
| Oct 3, 2021 | 0.51 |
| Jul 4, 2021 | 0.51 |
| Apr 4, 2021 | 0.48 |